BioCryst Closes Blackstone Loan and Astria Acquisition
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from BioCryst ( (BCRX) ).
On January 23, 2026, BioCryst Pharmaceuticals closed a $400 million term loan facility led by Blackstone and completed its acquisition of Astria Therapeutics in a transaction valued at about $700 million net of Astria’s cash. The secured term loans, maturing in 2031 with interest-only quarterly payments and customary covenants and prepayment premiums, are being used primarily to fund the cash portion of the merger consideration, related transaction costs, and general corporate purposes, and are backed by substantially all of BioCryst’s and its subsidiaries’ assets. Astria shareholders received a mix of cash and BioCryst stock, with approximately 37.3 million BioCryst shares issued at closing, and Astria became a wholly owned subsidiary, adding navenibart, a Phase 3 long-acting plasma kallikrein inhibitor that could offer every-three- or every-six-month HAE dosing, and early-stage atopic dermatitis candidate STAR0310, for which BioCryst plans to pursue strategic alternatives. The deal broadens BioCryst’s HAE franchise by pairing its established oral therapy ORLADEYO with a potential best-in-class injectable prophylactic, potentially strengthening its competitive position in the HAE market while also increasing leverage and shareholder dilution, and it brings new leadership talent from Astria onto BioCryst’s board and executive team to support pipeline development and commercialization.
The most recent analyst rating on (BCRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
The score is held back primarily by weak financial fundamentals (negative equity, leverage risk, and negative operating/free cash flow). Offsetting this, the latest earnings call was notably constructive with raised ORLADEYO guidance and improved non-GAAP profitability, while technicals are moderately positive and valuation remains unattractive due to a negative P/E and no dividend support.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor for HAE, and is advancing a pipeline of potential first- or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare conditions.
Average Trading Volume: 4,469,859
Technical Sentiment Signal: Sell
Current Market Cap: $1.41B
For an in-depth examination of BCRX stock, go to TipRanks’ Overview page.
